Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Syncona Limited
Deal Size : $17.7 million
Deal Type : Series A Financing
Yellowstone Biosciences Launches with £16.5 Million for TCR-based Cancer Therapies
Details : The financing aims to fund the Company in progressing its operational build, lead program in TCR-based therapies for the treatment of acute myeloid leukemia, and expand its pipeline.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Syncona Limited
Deal Size : $17.7 million
Deal Type : Series A Financing